Macular Degeneration

Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).

Cancer drug is no different in effectiveness as gold standard treatment for macular degeneration. Posted On: October 9, 2009 – 1:50pm (Boston) – Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare …